Assess whether a CMO finding is a delay or a refuse-to-file risk after a DSMB

Situation

FDA Response and Labeling work in a safety team sitting on a new disproportionate signal now turns on a CMO finding is because a DSMB note on an imbalance that is not yet a signal put phase-3 protocol with endpoint-sensitivity issues in play. Pharmacovigilance medical reviewer should say what phase-3 protocol with endpoint-sensitivity issues proves.

Decision

Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose A CMO finding is a delay / A refuse-to-file risk using phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• Pharmacovigilance medical reviewer can defend A CMO finding is a delay from phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal in a Pharma & Life Sciences challenge.
• Pharmacovigilance medical reviewer cannot defend A CMO finding is a delay from phase-3 protocol with endpoint-sensitivity issues; A refuse-to-file risk is what the extract actually supports after a DSMB note on an imbalance that is not yet a signal.
• A DSMB note on an imbalance that is not yet a signal never reached the population in phase-3 protocol with endpoint-sensitivity issues — reopen intake, do not close a CMO finding is.
• Two facts in phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal conflict for pharmacovigilance medical reviewer; hold this FDA Response and Labeling file.

Analysis required

• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences FDA Response and Labeling file, read phase-3 protocol with endpoint-sensitivity issues against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move a CMO finding is for pharmacovigilance medical reviewer.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / FDA Response and Labeling packet (phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal). Lead with the Pharma & Life Sciences option phase-3 protocol with endpoint-sensitivity issues can support after a DSMB note on an imbalance that is not yet a signal, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal.